<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002951</url>
  </required_header>
  <id_info>
    <org_study_id>8176</org_study_id>
    <secondary_id>UCCRC-8176</secondary_id>
    <secondary_id>NU-V96N1</secondary_id>
    <secondary_id>NCI-G97-1159</secondary_id>
    <nct_id>NCT00002951</nct_id>
  </id_info>
  <brief_title>Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer</brief_title>
  <official_title>Hyperfractionated Radiotherapy With Concomitant Fluorouracil and Hydroxurea for Intermediate Stage Cancer of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
      Combining radiation therapy with chemotherapy may kill more tumor cells.

      PURPOSE: Phase II trial to study the effectiveness of chemotherapy plus radiation therapy in
      treating patients with head and neck cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the locoregional control rates, time to failure, need for salvage surgery and
           overall survival of patients with intermediate stage cancer of the oral cavity, pharynx,
           larynx, paranasal sinuses, and cervical esophagus.

        -  Measure the impact of concomitant Hyper-FHX radiotherapy on organ preservation, organ
           function and quality of life parameters.

        -  Identify possible prognostic factors for toxic effects and response by performing
           pharmacologic monitoring.

      OUTLINE: Patients receive concomitant chemoradiotherapy with curative intent. Patients who
      have microscopic or macroscopic residual disease 6 weeks after completion of
      chemoradiotherapy will receive a surgical salvage procedure.

      The first cycle of chemotherapy will begin with PO doses of hydroxyurea every 12 hours on
      days 0-5. Fluorouracil is given IV on days 0-4. Radiation therapy BID is given on days 1-6.
      Cycles repeat every 14 days for a total of 5 cycles.

      The disease will be reevaluated 4-6 weeks after completion of all treatment, every 3 months
      for 1 year, then yearly.

      PROJECTED ACCRUAL: Approximately 40 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1996</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Locoregional control rate</measure>
    <time_frame>8 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A (Hyper-FHX)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concomitant chemoradiotherapy consisting of hydroxyurea (PO, BID, x 6days), continuous infusion 5-fluorouracil (IV, x 5days), hyperfractionated radiotherapy (150 cGy twice daily for 5 days every 14 days, 5 cycles)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <arm_group_label>Arm A (Hyper-FHX)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydroxyurea</intervention_name>
    <arm_group_label>Arm A (Hyper-FHX)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgical procedure</intervention_name>
    <arm_group_label>Arm A (Hyper-FHX)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>Arm A (Hyper-FHX)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed diagnosis of carcinoma

          -  Stage II-III (T2, T3, N0 or T1-3, N1) carcinoma of head and neck, including: oral
             cavity, pharynx, larynx, paranasal sinuses, and cervical esophagus

          -  No N2 or N3

          -  Measurable disease is not required

        PATIENT CHARACTERISTICS:

        Age:

          -  Not specified

        Performance status:

          -  Zubrod 0-3

        Life expectancy:

          -  Anticipated survival is 3-4 years (median)

        Hematopoietic:

          -  WBC count at least 3.5/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        Cardiovascular:

          -  Not specified

        Pulmonary:

          -  Not specified

        Other:

          -  No infection or severe medical illness

          -  Not pregnant

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  No prior radiotherapy

        Surgery:

          -  No prior surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Everett E. Vokes, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center, Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louis A. Weiss Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Evanston</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Cohen EE, Haraf DJ, List MA, Kocherginsky M, Mittal BB, Rosen F, Brockstein B, Williams R, Witt ME, Stenson KM, Kies MS, Vokes EE. High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial. J Clin Oncol. 2006 Jul 20;24(21):3438-44.</citation>
    <PMID>16849759</PMID>
  </results_reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 4, 2013</last_update_submitted>
  <last_update_submitted_qc>September 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II esophageal cancer</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <keyword>stage II nasopharyngeal cancer</keyword>
  <keyword>stage III nasopharyngeal cancer</keyword>
  <keyword>stage II lip and oral cavity cancer</keyword>
  <keyword>stage III lip and oral cavity cancer</keyword>
  <keyword>stage II hypopharyngeal cancer</keyword>
  <keyword>stage III hypopharyngeal cancer</keyword>
  <keyword>stage II laryngeal cancer</keyword>
  <keyword>stage III laryngeal cancer</keyword>
  <keyword>stage II paranasal sinus and nasal cavity cancer</keyword>
  <keyword>stage III paranasal sinus and nasal cavity cancer</keyword>
  <keyword>stage II oropharyngeal cancer</keyword>
  <keyword>stage III oropharyngeal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

